Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Core Insights - Karyopharm Therapeutics Inc. has appointed Kristin Abate as the Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024, while she continues as the interim principal financial officer [1][2] Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly oral compounds that address nuclear export dysregulation, a key mechanism in cancer development [3] - The company's lead product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets, including Europe, the UK, and China [3] - Karyopharm has a focused pipeline targeting high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]